Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

NCT02123823 ·Status: COMPLETED ·Phase: PHASE1

A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT02595762 ·Status: COMPLETED

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

NCT03515798 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

NCT03312738 ·Status: COMPLETED ·Phase: PHASE2

Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2

NCT02952729 ·Status: COMPLETED ·Phase: PHASE1

B002 in Patients With HER2-positive Breast Cancer

NCT04382352 ·Status: COMPLETED ·Phase: PHASE1

Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)

NCT02536625 ·Status: COMPLETED

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

NCT06125834 ·Status: RECRUITING ·Phase: PHASE2

Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

NCT00426556 ·Status: COMPLETED ·Phase: PHASE1

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

NCT00426530 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate the Safety and Effectiveness of Trastuzumab Emtansine (T-DM1) as Therapy in Chinese Participants With HER2 Positive Advanced Breast Cancer

NCT05945927 ·Status: COMPLETED

The Rechallenge of ADCs in MBC Patients

NCT05571618 ·Status: ACTIVE_NOT_RECRUITING

An Observational Study of Avastin (Bevacizumab) in Patients With HER2-metastatic or Locally Advanced Breast Cancer

NCT01461044 ·Status: COMPLETED

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer

NCT03566485 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

NCT02404051 ·Status: UNKNOWN ·Phase: PHASE3

Understanding and Anticipating Therapeutic and ADverse Responses in Anti-cancer Immune Checkpoint Inhibition Towards a Better Therapeutic Management of Patients

NCT05973344 ·Status: RECRUITING

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

NCT01805271 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

NCT06210776 ·Status: RECRUITING

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

NCT03184558 ·Status: TERMINATED ·Phase: PHASE2

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

NCT07254858 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

NCT00708214 ·Status: COMPLETED ·Phase: PHASE2

Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

NCT03842085 ·Status: RECRUITING ·Phase: PHASE1

A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein

NCT01918254 ·Status: COMPLETED ·Phase: PHASE1

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

NCT04132817 ·Status: COMPLETED ·Phase: PHASE1

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

NCT01240421 ·Status: APPROVED_FOR_MARKETING